TY - STD TI - Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, 2019. ID - ref1 ER - TY - JOUR AU - Calzetta, L. AU - Rogliani, P. AU - Matera, M. G. PY - 2016 DA - 2016// TI - A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD JO - Chest VL - 149 UR - https://doi.org/10.1016/j.chest.2016.02.646 DO - 10.1016/j.chest.2016.02.646 ID - Calzetta2016 ER - TY - JOUR AU - Calzetta, L. AU - Rogliani, P. AU - Ora, J. PY - 2017 DA - 2017// TI - LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment JO - Eur Respir Rev VL - 26 UR - https://doi.org/10.1183/16000617.0043-2016 DO - 10.1183/16000617.0043-2016 ID - Calzetta2017 ER - TY - JOUR AU - Hughes, A. D. AU - Jones, L. H. PY - 2011 DA - 2011// TI - Dual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary disease JO - Future Med Chem VL - 3 UR - https://doi.org/10.4155/fmc.11.106 DO - 10.4155/fmc.11.106 ID - Hughes2011 ER - TY - JOUR AU - Cazzola, M. AU - Page, C. P. AU - Calzetta, L. PY - 2012 DA - 2012// TI - Pharmacology and therapeutics of bronchodilators JO - Pharmacol Rev VL - 64 UR - https://doi.org/10.1124/pr.111.004580 DO - 10.1124/pr.111.004580 ID - Cazzola2012 ER - TY - JOUR AU - Aparici, M. AU - Carcasona, C. AU - Ramos, I. PY - 2019 DA - 2019// TI - Pharmacological profile of navafenterol (LAS191351), a novel inhaled dual M3 receptor antagonist/beta 2-Adrenoceptor agonist molecule with long-lasting effects and favorable safety profile JO - J Pharmacol Exp Ther VL - 370 UR - https://doi.org/10.1124/jpet.118.255620 DO - 10.1124/jpet.118.255620 ID - Aparici2019 ER - TY - JOUR AU - Jimenez, L. AU - Astbury, C. AU - Seoane, B. PY - 2017 DA - 2017// TI - A randomized placebo controlled trial of navafenterol a novel dual acting bronchodilator in asthmatics JO - Eur Respir J VL - 50 ID - Jimenez2017 ER - TY - STD TI - Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, 2015. ID - ref8 ER - TY - JOUR AU - Donohue, J. F. PY - 2005 DA - 2005// TI - Minimal clinically important differences in COPD lung function JO - COPD VL - 2 UR - https://doi.org/10.1081/COPD-200053377 DO - 10.1081/COPD-200053377 ID - Donohue2005 ER - TY - JOUR AU - Bateman, E. D. AU - Kornmann, O. AU - Ambery, C. PY - 2013 DA - 2013// TI - Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD JO - Pulm Pharmacol Ther VL - 26 UR - https://doi.org/10.1016/j.pupt.2013.03.015 DO - 10.1016/j.pupt.2013.03.015 ID - Bateman2013 ER - TY - JOUR AU - Bateman, E. D. AU - Ferguson, G. T. AU - Barnes, N. PY - 2013 DA - 2013// TI - Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study JO - Eur Respir J VL - 42 UR - https://doi.org/10.1183/09031936.00200212 DO - 10.1183/09031936.00200212 ID - Bateman2013 ER - TY - JOUR AU - Buhl, R. AU - Maltais, F. AU - Abrahams, R. PY - 2015 DA - 2015// TI - Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) JO - Eur Respir J VL - 45 UR - https://doi.org/10.1183/09031936.00136014 DO - 10.1183/09031936.00136014 ID - Buhl2015 ER - TY - JOUR AU - Psallidas, I. AU - Singh, D. AU - Astbury, C. PY - 2018 DA - 2018// TI - A phase 2a randomized, double-blind, placebo-controlled trial of navafenterol, a novel dual-acting bronchodilator in COPD patients JO - Am J Resp Crit Care Med VL - 197 ID - Psallidas2018 ER - TY - JOUR AU - Wielders, P. L. AU - Ludwig-Sengpiel, A. AU - Locantore, N. PY - 2013 DA - 2013// TI - A new class of bronchodilator improves lung function in COPD: a trial with GSK961081 JO - Eur Respir J VL - 42 UR - https://doi.org/10.1183/09031936.00165712 DO - 10.1183/09031936.00165712 ID - Wielders2013 ER - TY - JOUR AU - Singh, D. AU - Fuhr, R. AU - Jimenez, L. PY - 2019 DA - 2019// TI - A randomized trial of dual-acting bronchodilator navafenterol for chronic obstructive pulmonary disease JO - Am J Respir Crit Care Med VL - 199 UR - https://doi.org/10.1164/rccm.201812-2345LE DO - 10.1164/rccm.201812-2345LE ID - Singh2019 ER - TY - JOUR AU - Battisti, W. P. AU - Wager, E. AU - Baltzer, L. PY - 2015 DA - 2015// TI - Good publication practice for communicating company-sponsored medical research: GPP3 JO - Ann Intern Med VL - 163 UR - https://doi.org/10.7326/M15-0288 DO - 10.7326/M15-0288 ID - Battisti2015 ER -